Medical News

RSS

VeriChip to commence Phase II development of an in vivo glucose-sensing RFID microchip

VeriChip Corporation and its development partner RECEPTORS LLC, a technology company whose AFFINITY by DESIGN chemistry platform can be applied to the development of selective binding products, announced today that VeriChip plans to fund its existing development partnership with RECEPTORS to launch Phase II development of an in vivo glucose-sensing RFID microchip.

1 Oct 2009

Advaxis announces Phase I trial results of its ADXS11-001 therapeutic cancer vaccine

The Phase I trial of ADXS11-001, the lead vaccine candidate of Advaxis, Inc. (OTCBB: ADXS), the company that pioneered the live, attenuated Listeria monocytogenes (Lm) vaccine, has shown thirty-six (36) month survival in three (3) of the thirteen (13) evaluable patients treated with Advaxis’ therapeutic cancer vaccine, indicating the possibility of persistent immune protection.

1 Oct 2009

Clinical study results of prostate cancer patients treated with CyberKnife Radiosurgery released

Accuray Incorporated, a global leader in the field of radiosurgery, announced today publication of results from a study of early stage prostate cancer patients treated with CyberKnife Radiosurgery.

1 Oct 2009

New website launched provides details on breast cancer risks faced by younger women

A website launched to coincide with National Breast Cancer Awareness Month, at www.earlyactawareness.org, provides a powerful focal point for efforts to pass the EARLY Act.

1 Oct 2009

First prescription foam formulation of benzoyl peroxide available

Onset Therapeutics, a specialty pharmaceutical company focused on dermatology, announced today the commercial availability of BenzEFoam (benzoyl peroxide) 5.3% Emollient Foam, the first prescription foam formulation of benzoyl peroxide.

1 Oct 2009

Health Canada approves VIBATIV for treating complicated skin and skin structure infections

Astellas Pharma Canada, Inc. announced today that Health Canada has approved VIBATIV(TM) (telavancin) for the treatment of adult patients with complicated skin and skin structure infections (cSSSI) caused by susceptible Gram-positive bacteria, including Staphylococcus aureus, both methicillin-resistant (MRSA) and methicillin-susceptible (MSSA) strains.

1 Oct 2009

Phase 2 study of PH20 with regular human insulin confirms faster insulin absorption

Halozyme Therapeutics, Inc. today announced additional Phase 2 results that demonstrated faster insulin absorption and increased peak insulin concentrations in type 1 diabetic patients after co-administration of its recombinant hyaluronidase enzyme (rHuPH20 or PH20) with Humulin® R (regular human insulin), a mealtime insulin.

1 Oct 2009

NCI selects Integral Molecular to map epitopes for monoclonal antibodies

Integral Molecular, Inc. has been selected by the National Cancer Institute (NCI) to map epitopes for monoclonal antibodies directed against cancer biomarkers. Protein targets of interest to the Clinical Cancer Proteomics community will be analyzed using Shotgun Mutagenesis Mapping technology to identify amino acids that are essential for antibody binding, allowing the discovery and characterization of cancer-specific biomarkers.

1 Oct 2009

Talyst collaborates with healthcare consultancy to provide implementation services

Talyst, a leader in pharmacy automation systems, announced today a partnership with RXinnovate, a healthcare consultancy, to offer top-of-the-line implementation services to Talyst's clients in the acute care industry.

1 Oct 2009

Cross Atlantic Commodities and Mercatis Media sign Online Advertising Agreement

Cross Atlantic Commodities, Inc. (Pink Sheets:CXAC), a successful manufacturer of specialty health and beauty products, announced signing an Online Advertising Agreement with Mercatis Media, LLC, Los Angles California.

1 Oct 2009

Women create nationwide movement to eradicate breast cancer

More than 300,000 women from across the U.S. have signed up for the Love/Avon Army of Women creating a nationwide movement to eradicate breast cancer. Eighty percent of the women who have joined the Army of Women have never had breast cancer, but want to play a role in ending the disease once and for all.

1 Oct 2009

CVRx commences enrollment in study evaluating the Rheos System to treat heart failure

CVRx, Inc. reported the first enrollment of a patient in the HOPE4HF Trial, a study that is evaluating the Rheos System to treat heart failure. The Rheos System uses Baroreflex Activation Therapy® technology, an entirely new non-pharmaceutical approach designed to treat cardiovascular disease. The HOPE4HF Trial is being conducted under an approved investigational device exemption (IDE) from the U.S. Food and Drug Administration (FDA).

1 Oct 2009

Addrenex submits a sNDA to the FDA for Clonicel

Sciele Pharma, Inc., a Shionogi company, and Addrenex Pharmaceuticals today announced that Addrenex has submitted a supplemental New Drug Application (sNDA) to the United States Food and Drug Administration (FDA) for Clonicel (modified-release clonidine) to treat attention deficit hyperactivity disorder (ADHD).

1 Oct 2009

Resorbable Orthopedics becomes wholly owned subsidiary of Wound Management Technologies

Wound Management Technologies, Inc., (OTC Bulletin Board: WNDM) a rapidly growing provider of specialty medical products, announced today it has closed on its acquisition of Resorbable Orthopedics LLC, a private company with patented technologies including a resorbable bone wax and a delivery system for orthopedic bone void fillers, among others.

1 Oct 2009

The HealthWell Foundation 's panel discussion draws attention on growing crisis of the underinsured

On Tuesday, September 22, 2009, The HealthWell Foundation, one of America's largest co-payment assistance organizations, hosted a panel discussion to help draw attention to the growing crisis of the underinsured and the related challenges of reducing financial barriers to care.

1 Oct 2009

Diamyd Medical signs agreement with Inclinix to conduct global Phase III program

Diamyd Medical announces today that the company has signed an agreement with Inclinix Inc., North Carolina, for accelerated recruitment of children and adolescents recently diagnosed with type 1 diabetes in the US Phase III study of the diabetes vaccine Diamyd(R).

1 Oct 2009

TriPollar technology effective in reducing stretch marks

Dr. Worophong Manuskiatti has been invited to present results of his study "Treatment of striae distensae in skin phototypes IV-V with a TriPollar radiofrequency device" in the upcoming meeting of the European Academy of Dermatology and Venereology (EADV) Conference held on October 7-10, 2009 in Berlin, Germany.

1 Oct 2009

Scientific Advisory Board to provide guidance to support the development of FST-100

Foresight Biotherapeutics announced today the formation of its scientific advisory board to provide guidance to the company for the development of it’s lead product FST-100, a novel formulation of dexamethasone that includes povidone-iodine. Foresight’s Scientific Advisory Board is comprised of leaders in the field of Ophthalmology.

1 Oct 2009

Individuals invited to participate in National Board written exam pilot

The National Board of Certification for Medical Interpreters continues to advance towards the launch of a single national certification process that will award individuals the credential of "Certified Medical Interpreter" (CMI) in a specific language. It recently concluded the pilot of the National Board oral exam and commenced the pilot of the National Board written exam with an open call to the field for participants.

1 Oct 2009

RSB Spine signs master distribution agreement with Paradigm BioDevices

RSB Spine, LLC, today announced that it has signed an exclusive master distribution agreement with Paradigm BioDevices, Inc. for the U.S. market. Paradigm BioDevices was instrumental in developing the Stand Alone 360 market for ZERO-Profile(SM) ALIF implants, which is one of the fastest growing segments in the spine market.

1 Oct 2009

Medical News

VeriChip to commence Phase II development of an in vivo glucose-sensing RFID microchip

Advaxis announces Phase I trial results of its ADXS11-001 therapeutic cancer vaccine

Clinical study results of prostate cancer patients treated with CyberKnife Radiosurgery released

New website launched provides details on breast cancer risks faced by younger women

First prescription foam formulation of benzoyl peroxide available

Health Canada approves VIBATIV for treating complicated skin and skin structure infections

Phase 2 study of PH20 with regular human insulin confirms faster insulin absorption

NCI selects Integral Molecular to map epitopes for monoclonal antibodies

Talyst collaborates with healthcare consultancy to provide implementation services

Cross Atlantic Commodities and Mercatis Media sign Online Advertising Agreement

Women create nationwide movement to eradicate breast cancer

CVRx commences enrollment in study evaluating the Rheos System to treat heart failure

Addrenex submits a sNDA to the FDA for Clonicel

Resorbable Orthopedics becomes wholly owned subsidiary of Wound Management Technologies

The HealthWell Foundation 's panel discussion draws attention on growing crisis of the underinsured

Diamyd Medical signs agreement with Inclinix to conduct global Phase III program

TriPollar technology effective in reducing stretch marks

Scientific Advisory Board to provide guidance to support the development of FST-100

Individuals invited to participate in National Board written exam pilot

RSB Spine signs master distribution agreement with Paradigm BioDevices

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Evolving spectrophotometry for modern biopharma workflows

Latest News